BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badve SV, Hawley CM, Johnson DW. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology (Carlton) 2011;16:144-53. [PMID: 21272125 DOI: 10.1111/j.1440-1797.2010.01407.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Atkinson MA, Warady BA. Anemia in chronic kidney disease. Pediatr Nephrol 2018;33:227-38. [PMID: 28412770 DOI: 10.1007/s00467-017-3663-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
2 Morrish AT, Hawley CM, Johnson DW, Badve SV, Perkovic V, Reidlinger DM, Cass A. Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney Int 2014;85:23-30. [PMID: 24088955 DOI: 10.1038/ki.2013.391] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Harrison LE, Burton JO, Szeto CC, Li PK, McIntyre CW. Endotoxaemia in haemodialysis: a novel factor in erythropoetin resistance? PLoS One 2012;7:e40209. [PMID: 22768256 DOI: 10.1371/journal.pone.0040209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
4 Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Am J Kidney Dis 2015;65:49-57. [PMID: 25115616 DOI: 10.1053/j.ajkd.2014.06.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
5 Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 2014;29:2021-8. [PMID: 24794833 DOI: 10.1007/s00467-014-2820-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
6 Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group. Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Can J Kidney Health Dis 2015;2:33. [PMID: 26284153 DOI: 10.1186/s40697-015-0066-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Badve SV, Beller EM, Cass A, Francis DP, Hawley C, Macdougall IC, Perkovic V, Johnson DW. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev 2013;:CD006861. [PMID: 23979995 DOI: 10.1002/14651858.CD006861.pub3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]